<DOC>
	<DOCNO>NCT01980589</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose carfilzomib give twice weekly combination cyclophosphamide dexamethasone patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>A Multicenter , Open-label , Phase 1b Study Carfilzomib , Cyclophosphamide Dexamethasone Newly Diagnosed Multiple Myeloma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Newly diagnose multiple myeloma 2 . Measurable disease , define 1 follow Serum Mprotein ≥ 0.5 g/dL , Urine Mprotein ≥ 200 mg/24 hour , In subject without detectable serum urine Mprotein , serum free light chain ( SFLC ) &gt; 100 mg/L ( involved light chain ) abnormal kappa lambda ( κ/λ ) ratio 3 . Males females ≥ 18 year age 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 5 . Adequate hepatic function 6 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % 7 . Absolute neutrophil count ( ANC ) ≥ 1.0 × 10^9/L 8 . Platelet count ≥ 50 × 10^9/L 9 . Calculated measured creatinine clearance ( CrCl ) ≥ 15 mL/min 1 . Planned autologous hematopoietic stem cell transplantation ( HSCT ) initial therapy newly diagnose multiple myeloma 2 . Multiple myeloma immunoglobulin M ( IgM ) subtype 3 . Prior systemic treatment multiple myeloma 4 . Glucocorticoid therapy within 14 day prior enrollment equal exceed equivalent dexamethasone 160 mg 5 . Known amyloidosis 6 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within 6 month prior enrollment . 7 . Known human immunodeficiency virus ( HIV ) seropositive , hepatitis C infection , and/or hepatitis B ( subject hepatitis B surface antigen [ SAg ] core antibody receive respond antiviral therapy direct hepatitis B allow ) 8 . Significant neuropathy ( Grades ≥ 2 ) within 14 day prior enrollment 9 . Any clinically significant medical disease condition , investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>multiple myeloma</keyword>
</DOC>